Join free
Sign inSign up free
← Back to Blog
GLP-1 / Weight Loss11 min read

What the GLP-1 Pipeline Showed at ADA 2026: Retatrutide, CagriSema, Orforglipron

What the GLP-1 Pipeline Showed at ADA 2026: Retatrutide, CagriSema, Orforglipron

The American Diabetes Association's 86th Scientific Sessions wrapped in New Orleans on June 8, 2026, and it was the biggest single dump of GLP-1 data this year. Three drugs that people in the research-compound world actually track all read out at the same conference: retatrutide, CagriSema, and orforglipron. Here's what each one is, what it showed, and — because this is the part the press releases bury — what the caveats are. [1][5]

Retatrutide: the triple agonist posts surgery-level numbers

Retatrutide is the one most people on r/Retatrutide and r/GLP1Sourcing are watching. It's a once-weekly triple agonist — it hits GLP-1, GIP, and glucagon receptors, where semaglutide hits one and tirzepatide hits two. More targets, in theory, means more weight loss. The ADA data backed that up. [2]

TRIUMPH-1 (obesity). In adults with obesity, the highest dose drove an average of 28.3% body-weight loss — about 70.3 lbs — at 80 weeks. The headline stat: 45.3% of participants on the top dose lost 30% or more of their body weight, a threshold that historically only bariatric surgery reached. [2][3]

TRANSCEND-T2D-1 (type 2 diabetes). In adults with type 2 diabetes, retatrutide lowered A1C by up to 2.0% and cut weight by up to 16.8% (about 36.6 lbs) at 40 weeks. These results were published simultaneously in The Lancet. [4][5]

It wasn't just weight and glucose. Lilly also reported that retatrutide improved knee osteoarthritis pain and obstructive sleep apnea — the "GLP-1s treat the complications of obesity, not just the obesity" story that ran through the whole conference. [6]

The honest caveat. A novel safety signal showed up: urinary tract infections appeared in roughly 7.5%–8.8% of retatrutide participants versus 5.3% on placebo. It's not a dealbreaker, but it's new, and it's worth tracking as the program matures. [1] And retatrutide is still investigational — Lilly is expected to file its application in 2026, with approval most likely in 2027 or 2028. None of the data above means it's available as an approved drug yet. We broke down the bigger regulatory question in our piece on the retatrutide drug-vs-biologic classification fight, and there's a full retatrutide research profile in the library.

CagriSema: Novo's amylin + GLP-1 answer

CagriSema is Novo Nordisk's counter-punch. It's a fixed-dose combination of cagrilintide — a long-acting amylin analog — and semaglutide, the GLP-1 you already know. Amylin is a different appetite-regulating hormone, so CagriSema stacks two mechanisms rather than piling more agonism onto the incretin pathway. [7]

At ADA 2026, Novo presented the first diabetes data for CagriSema from the REIMAGINE trial program (REIMAGINE-1, -2, and -3), spanning monotherapy, head-to-head component comparisons, and a basal-insulin add-on. The trials met their primary A1C endpoints and confirmed secondary weight-loss endpoints. [1][7]

CagriSema is further along the regulatory path than retatrutide — Novo filed its application in late 2025, and an FDA decision is expected in the second half of 2026. So of these three, CagriSema is the one most likely to actually reach the market first. [5]

Orforglipron: the oral one (that isn't a peptide)

Orforglipron — Lilly's brand name is Foundayo — got its own ADA symposium on June 8. It's an oral GLP-1, and notably the only one that can be taken without food or water restrictions, which is a real-world adherence advantage over the empty-stomach oral drugs. [3]

One thing worth keeping straight, because it surprises people: orforglipron is a small molecule, not a peptide. That's exactly why it survives the gut as a daily pill. We unpacked that distinction — and why it matters for where peptide drugs are heading — in orforglipron, the first oral GLP-1 pill, and its mirror image in enlicitide, the cholesterol pill that's secretly a peptide.

The bigger theme: GLP-1s stopped being single-goal drugs

If there was one through-line at ADA 2026, it's that the field has stopped treating these as "diabetes drugs" or "weight-loss drugs" and started treating them as multi-organ metabolic drugs — knee pain, sleep apnea, kidney, liver, heart. [1] We dug into that expansion separately in GLP-1s are becoming "everything" drugs, including the indications that have failed, which the hype tends to skip.

The takeaway

ADA 2026 was a strong showing for the GLP-1 pipeline: retatrutide hit surgery-level weight loss, CagriSema validated the amylin-plus-GLP-1 approach, and orforglipron kept the oral race alive. But the honest reading is that two of the three are still investigational, retatrutide picked up a new UTI signal, and none of the surrogate numbers prove long-term cardiovascular outcomes yet. The legitimate pipeline is moving fast — which is exactly why the gray-market versions of these compounds keep multiplying. If you're comparing research sources, that's all the more reason to weigh vendor COA verification heavily.

This article summarizes publicly reported clinical-trial data presented at ADA 2026 for educational purposes and is not affiliated with Eli Lilly or Novo Nordisk. Retatrutide and CagriSema are investigational. For research purposes only. Not for human consumption. Not medical advice. Always consult a licensed physician.

Sources

  1. TechTimes. "GLP-1 Drugs 2026: ADA Sessions Close as New Standards End Single-Goal Diabetes Care." techtimes.com
  2. The Pharmaceutical Journal. "Phase III retatrutide study demonstrates 30% weight loss." pharmaceutical-journal.com
  3. Lilly / PRNewswire. "Lilly to present new data on Foundayo, Mounjaro and retatrutide at the ADA's 86th Scientific Sessions." prnewswire.com
  4. Managed Healthcare Executive. "Retatrutide shows substantial weight loss, glycemic control in obesity and type 2 diabetes | ADA 2026." managedhealthcareexecutive.com
  5. Medscape. "Retatrutide Data Show Dramatic Weight Loss, Other Benefits." medscape.com
  6. BioSpace. "Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea." biospace.com
  7. BioSpace. "Lilly and Novo face off at ADA 2026 as others seek to compete in obesity." biospace.com
Failed to fetch